ORGO Organogenesis Holdings (A)

Organogenesis Holdings Inc. to Participate in the ICR Conference 2021

Organogenesis Holdings Inc. to Participate in the ICR Conference 2021

CANTON, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that company management will attend the ICR Conference 2021, which is being held virtually from January 11th-14th. Management will participate in a fireside chat on Thursday, January 14th at 1:45 p.m. Eastern Time.

A live audio webcast of the conference presentation will be accessible by visiting the “Upcoming Events” section on the “Investor Relations” page of Organogenesis’s website An archive of the webcast will be available for replay following the conference for approximately 30 days.

About Organogenesis Holdings Inc.

Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit .



Investor Inquiries:
Westwicke Partners
Mike Piccinino, CFA
 
443-213-0500

Press and Media Inquiries:
Organogenesis
Marcus Girolamo
  
817-688-4767
EN
05/01/2021

Underlying

ORGOOrganogenesis Holdings (A)

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Organogenesis Holdings (A)

 PRESS RELEASE
Free
ORGO Organogenesis H...

Organogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq L...

Organogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CANTON, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (the “Company”) (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that effective October 29, 2025, the Company’s Board of Directors granted inducement awards to Michael Catarina, the Company’s newly hired Chief Technology Officer, consisting of non-st...

October 31, 2025 1 EN
 PRESS RELEASE
Free
ORGO Organogenesis H...

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 202...

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025 CANTON, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that third quarter of fiscal year 2025 financial results will be reported after the market closes on Thursday, November 6th. Management will host a conference call at 5:00 p.m. East...

October 1, 2025 1 EN
 PRESS RELEASE
Free
ORGO Organogenesis H...

Organogenesis Provides Update on Second Phase 3 ReNu® Study

Organogenesis Provides Update on Second Phase 3 ReNu® Study Company maintains confidence in ReNu as innovative pain management therapy Second Phase 3 trial demonstrates numerical improvement in baseline pain reduction over the first Phase 3 trial despite not meeting the primary endpointStatistically significant maintenance of function (p

September 25, 2025 1 EN
 PRESS RELEASE
Free
ORGO Organogenesis H...

Organogenesis Holdings Inc. to Participate in Upcoming Investor Confer...

Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September CANTON, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that management will participate in the following upcoming investor conferences: The Cantor Fitzgerald Global Healthcare Conference at the New York Marriott Marquis in New York, NY Management will partic...

August 27, 2025 1 EN
 PRESS RELEASE
Free
ORGO Organogenesis H...

Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Resu...

Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results CANTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Summary: Net product revenue of $100.8 million for the second quarter of 2025, a decrease of $29.5 million compared...

August 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch